Quantcast

Industry news that matters to you.  Learn more

PDI, Inc. Subsidiary Interpace Diagnostics Announces New Data Supporting Use of ThyraMIR – First and Only MicroRNA Gene Expression Classifier – with ThyGenX Thyroid Oncogene Panel to Improve Identification of Both Benign and Malignant Thyroid Nodules

PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, announced today new data supporting the use of combination platform testing with ThyraMIR™, the first and only microRNA expression classifier, and ThyGenX™ Thyroid Oncogene Panel, a DNA and RNA mutational analysis, to improve thyroid cancer diagnosis. The study, presented at ENDO 2015: The 97th Annual Meeting & Expo of the Endocrine Society held March 5-8, 2015 in San Diego, CA, showed that benign or malignant nodules can be identified with high sensitivity and specificity resulting in clinically actionable negative predictive value (NPV) at 94% and positive predictive value (PPV) at 74%. The effect of combining nucleic acid sequencing with a gene classifier significantly improved the tests’ ability to correctly identify both benign and malignant nodules, potentially resulting in fewer unnecessary surgeries.

PDI, Inc. Subsidiary Interpace Diagnostics Announces New Data Supporting Use of ThyraMIR – First and Only MicroRNA Gene Expression Classifier – with ThyGenX Thyroid Oncogene Panel to Improve Identification of Both Benign and Malignant Thyroid Nodules

PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, recently announced new data supporting the use of combination platform testing with ThyraMIR™, the first and only microRNA expression classifier, and ThyGenX™ Thyroid Oncogene Panel, a DNA and RNA mutational analysis, to improve thyroid cancer diagnosis. The study, presented at ENDO 2015: The 97th Annual Meeting & Expo of the Endocrine Society held March 5-8, 2015 in San Diego, CA, showed that benign or malignant nodules can be identified with high sensitivity and specificity resulting in clinically actionable negative predictive value (NPV) at 94% and positive predictive value (PPV) at 74%. The effect of combining nucleic acid sequencing with a gene classifier significantly improved the tests’ ability to correctly identify both benign and malignant nodules, potentially resulting in fewer unnecessary surgeries.

PDI, Inc. Subsidiary Interpace Diagnostics Announces Launch of ThyGenX Next-Generation Sequencing (NGS) Test for Cancer Risk Assessment of Thyroid Nodules

PDI, Inc. (Nasdaq: PDII) recently announced that its molecular diagnostics subsidiary, Interpace Diagnostics, has launched its new next-generation sequencing (NGS) ThyGenX™ test to assist physicians in distinguishing between benign and malignant genotypes in indeterminate thyroid nodules.  Over 525,000 thyroid FNA’s (fine needle aspirates) are performed annually and up to 30% of the results are indeterminate.  ThyGenX is used to improve risk stratification to help minimize the need for unnecessary surgical procedures when standard cytopathology does not provide a clear diagnosis of thyroid cancer.